Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: Development of chemical probe …

…, SW Gerritz, FJ Schoenen, CJ Thomas, J Aubé

Index: Coombs, Thomas C.; Tanega, Cordelle; Shen, Min; Wang, Jenna L.; Auld, Douglas S.; Gerritz, Samuel W.; Schoenen, Frank J.; Thomas, Craig J.; Aube, Jeffrey Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 12 p. 3654 - 3661

Full Text: HTML

Citation Number: 19

Abstract

Substituted pyrimidine inhibitors of the Clk and Dyrk kinases have been developed, exploring structure–activity relationships around four different chemotypes. The most potent compounds have low-nanomolar inhibitory activity against Clk1, Clk2, Clk4, Dyrk1A and Dyrk1B. Kinome scans with 442 kinases using agents representing three of the chemotypes show these inhibitors to be highly selective for the Clk and Dyrk families. Further off-target ...

Related Articles:

Design, synthesis and structure–activity relationship (SAR) studies of 2, 4-disubstituted pyrimidine derivatives: Dual activity as cholinesterase and Aβ-aggregation …

[Mohamed, Tarek; Zhao, Xiaobei; Habib, Lila K.; Yang, Jerry; Rao, Praveen P.N. Bioorganic and Medicinal Chemistry, 2011 , vol. 19, # 7 p. 2269 - 2281]

Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity

[Chen, Kuen-Feng; Pao, Kuan-Chuan; Su, Jung-Chen; Chou, Yi-Chieh; Liu, Chun-Yu; Chen, Hui-Ju; Huang, Jui-Wen; Kim, Inki; Shiau, Chung-Wai Bioorganic and Medicinal Chemistry, 2012 , vol. 20, # 20 p. 6144 - 6153]

More Articles...